Clinical Trials

Clinical Research and Trials on Diabetes / Cancer / AIDS

Submit Abstract Register Now

Cancer is a group of more than 100 different diseases characterized by the uncontrolled, abnormal growth of cells. These cells form a lump or mass called a tumor. Cancers are divided in to types based on where it begins.

·         Carcinomas: A carcinoma begins in the skin or the tissue that covers the surface of internal organs and glands. Carcinomas usually form solid tumors. They are the most common type of cancer. Examples of carcinomas include prostate cancer, breast cancer, lung cancer, and colorectal cancer.

• Sarcomas: A sarcoma begins in the tissues that support and connect the body. A sarcoma can develop in fat, muscles, nerves, tendons, joints, blood or lymph vessels, cartilage, or bone.
• Leukemias: Leukemia is a cancer of the blood. Leukemia begins when healthy blood cells change and grow uncontrollably. The four main types of leukemia are acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia.
• Lymphomas: Lymphoma is a cancer that begins in the lymphatic system. The lymphatic system is a network of vessels and glands that help fight infection. There are two main types of lymphomas: Hodgkin lymphoma and non-Hodgkin lymphoma.
• In this session we listed most common and major cancers in male and female to discuss, example Breast Cancer, Brain cancer, Liver cancer, Blood cancer, Brain cancer, Prostate cancer, Kidney cancer and Pancreatic Cancer etc.

The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer. Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.